|
Current Gene Therapy
ISSN: 1566-5232 - Volume 8, 6 Issues, 2008
Instructions for
Authors
JOURNAL SCOPE
Current Gene Therapy (CGT) is a bimonthly interdisciplinary
peer-reviewed journal, aimed at academic and industrial scientists
with an interest in major topics concerning basic and clinical
applications of gene therapy. It provides a forum for reviews
on the latest developments on gene transfer and gene expression
analysis, animal models, vector development, and human clinical
applications for the treatment of diseases. Current Gene Therapy
is indexed in Chemical Abstracts, BIOSIS, Index Medicus/MEDLINE,
EMBASE, Cambridge Scientific Abstracts (CSA), SCIE, Index
of Scientific Reviews, Biotechnology Citation Index, Current
Contents/Life Sciences, and ISI.
MANUSCRIPT SUBMISSION
Manuscripts may also be submitted openly to the Editor-in-Chief
without prior invitation.
Reviews provide the reader with a comprehensive assessment
of any area of experimental biology applied to molecular medicine
that is not only of significance within a particular field
of gene therapy but also of interest to investigators in other
fields. Authors are encouraged to provide their own assessment
and vision for future advances. Reviews are also welcome on
late breaking discoveries on which substantial literature
has not yet been amassed. Such reviews provide a forum for
sharply focused topics of recent experimental investigations
in gene therapy primarily to make these results accessible
to both clinical and basic researchers. They should therefore
be a critical but balanced assessment of the field and should
not dwell on authors' own published experimental results.
Please submit your manuscript to the CGT Editorial Office
at cgt@univ-nantes.fr
and provide us with the following:
- A cover letter including the corresponding author's contact
information (address, telephone and fax numbers, email), the
number of figures and tables and word count.
- An electronic copy of the Manuscript (Word) including figures
and tables.
In order to expedite the review process, you may provide us
with a list of 5 potential reviewers and their contact information
including email.
A successful electronic submission of a manuscript will be
followed by a system-generated acknowledgement to the principal/corresponding
author within 72 hours of the dispatch of the manuscript.
Any queries therein should be addressed to mahmood@bentham.org
and copied to Jalil@bentham.org
MANUSCRIPT PREPARATION
All manuscripts should be written in English and should not
exceed 60 pages (25 printed pages), including, references,
tables and figures. They should be submitted as Microsoft
Word (DOC), rich text (RTF), or PDF files.
Title Page: The title page should contain the title,
authorship (First name, middle name (initials) and surname
only), affiliations, name of the corresponding author. The
principal author should be denoted with an asterisk.
Abstract: The abstract should not exceed 250 words.
Keywords: A list of eight key words that are not included
in the title should be provided. Please refer to standard
MeSH-Medline major subject headings.
Abbreviations: Abbreviations should be defined the
first time they appear in the text. A list of all abbreviations
used should be provided.
Text: The main text should begin on a separate page
and may be subdivided into separate sections. The review article
should mention any previous important reviews in the field
and contain a comprehensive discussion starting with the general
background of the field. It should then go on to discuss the
salient features of recent developments. The authors should
avoid presenting material, which has already been published
in a previous review.
Acknowledgements: All sources of financial support
should be mentioned along with specific statements regarding
potential competing financial interests. Please refer to the
competing financial interests section for details.
References: References should be numbered sequentially
[in square brackets] in the text and listed in the same numerical
order in the reference section.
All references must be complete and accurate. Online citations
should include the date of access. Journal titles should conform
to the present Index Medicus abbreviations. It is necessary
to list all authors if the total number of authors is 6 or
less and for more than 6 authors use 3 authors and then et
al. References should be listed in the following Vancouver
style:
Journal Articles:
[1] Abbas AK, Janeway CA. Immunology: improving on nature
in the twenty-first century. Cell 2000; 100: 129-38.
[2] Beltrami AP, Urbanek K, Kajstura J, et al. Evidence
that human cardiac myocytes divide after myocardial infarction.
N Engl J Med 2001; 344: 1750-57.
[3] French AW. Gene therapy: the best of times, the worst
of times. Science 2000; 288: 627-9.
Books:
[4] Lowenstein PR, Enquist L. Protocols for gene transfer
in neuroscience: towards gene therapy of neurological disorders.
John Wiley and Sons, Chichester 1996.
Book Chapters:
[5] Streilein JW, Taylor AW. Immunologic principles related
to the nervous system and the eye: concerning the existence
of a neural-ocular immune system. In: Hickey WF, Keans RW
Eds , Immunology of the nervous system. New York, Oxford University
Press 1997; pp. 99-133.
Abstracts, unpublished data, and personal communications (which
can be only included if permission has been obtained) should
not be given in the references section but they may be mentioned
in the text and details provided as footnotes.
Tables: Each table should include a title/caption.
Detailed legends may be included. Vertical rules should not
be used. Tables should be numbered in Arabic numerals based
on the order in which they appear in the text. They should
be referred to as “(Table 1)”, “(Table 2)”
etc. in the text with numbers in bold and in parentheses.
References should be quoted in tables as name and year within
square brackets as follows: [Abbas et al., 2000;
Cavazzana-Calvo et al., 2000].
FIGURES & ILLUSTRATIONS
Numbering: Figures should be numbered in Arabic numerals
based on the order in which they appear in the text. They
should be referred to as "(Fig. 1)", "(Fig.
2)" etc. in the text with figure numbers in bold
and in parentheses.
Format, Resolution, and Size: The following file
formats can be accepted: PDF, TIFF, JPEG, GIF. Please bear
in mind that illustrations must fit a single (height, 24 cm
max.; width, 8.5 cm max) or double-column (height, 24 cm max.;
width, 18 cm max.) width. Whenever possible, submit graphics
that do not have to be reduced to fit the standard figure
size. Use the best resolution available. Avoid textures and
shadings giving a three-dimensional effect to the illustration.
Symbols and lettering in the illustration should be of similar
size. For line drawings, lines should be clear and sharp and
should be of uniform density. Moreover, lines should be continuous
without any breaks. Do not use lines thinner than 1 point.
Preferred fonts are Times New Roman or Helvetica, font size
should exceed 10 pt. Color figures should be provided in CMYK
format, not RGB. Required resolution is at least 300 dpi.
Photographs: Submit high-contrast photographs that
fit single or double-column width so that they will not have
to be reduced when printed. Negatives are not acceptable.
Chemical Structures: Chemical structures must be prepared
using ChemDraw (any version) and should be provided on separate
pages. They must fit single or double-column width.
REVIEW PROCESS
All papers submitted for publication will be immediately subjected
to editorial scrutiny and peer-review. Reviewing is always
performed by at least two reviewers and at least one of them
external to the Editorial Board. Written reviews are provided
to authors. Every effort will be made to assess the papers
quickly. The decision is usually transmitted to the corresponding
author within 6 weeks from the date of submission.
ACCEPTED MANUSCRIPTS
Copyediting and Production: Copyediting and production of
accepted manuscripts is handled by our production office.
Please address all correspondence to Ms. Anila Mufti at cgt@bentham.org
Page Charges: The cost for the first published page of color figures is US$ 780; the second additional page will be for US$ 570, and each subsequent page for US$ 385.
- Color figures should be supplied in CMYK not
RGB colors.
- Required resolution for online submission
is 300 dpi. In case of hardcopy submission, please use the
maximum resolution available. In case the figure(s) are
of an inferior quality they will need to be improved either
by the author or by the publisher on a charged basis.
Language Editing: Manuscripts submitted
containing many English typographical errors will not be published.
Authors from non-English language countries are advised to
use the services of our professional language editing department
prior to submitting their manuscript to the Journal. Please
contact Bentham Publishing Services www.benthampublishingservices.com
for a language editing quote at e-mail: info@benthampublishingservices.com
stating the total number of words of the article to be edited.
Proofs: Authors are sent page proofs. To avoid delays
in publication, proofs should be checked immediately for typographical
errors and returned within 48 hours. Authors will be charged
for excessive changes made at the page proof stage.
Bentham Open Access: Accepted articles
can be published online for free open access for all to view.
Open access publishing provides the maximum dissemination
of the article to the largest audience. Authors must pay for
this service. All corresponding authors will be asked to indicate
whether or not they wish to pay to have their paper made freely
available on publication. If authors do not select the Open
Access option, then their article will be published with standard
subscription-based access at no charge. Open access articles
are published under the terms of the Creative Commons Attribution
Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)
which permits unrestricted, non-commercial use, distribution
and reproduction in any medium, provide the work is properly
cited.
Bentham Science offers authors the choice of open access publication
of their articles at a fee of US$ 2,800 per published article
which allows indefinite online publication with BOTH Bentham
Science, PubMed Central and UK PubMed Central. For more information
please contact us at e-mail: openaccess@bentham.org
Reviewing and Promptness of Publication: The Guest
Editor of the theme issue will be responsible to carefully
evaluate the suitability of the manuscript for publication,
and to make editorial changes if required. The Guest Editor
has full freedom to forward the manuscript to the experts
working in the field for evaluation. After the reviewing process,
the Guest Editor shall forward the collection of manuscripts
to the Editor-in-Chief for further consideration and publication.
The Editor-in-Chief shall reserve the right to return manuscripts
to the Guest Editor or to make relatively minor editorial
changes as deemed appropriate.
Reprints: The corresponding author, at
no cost, will be provided with a PDF file of the article electronically.
The PDF file will be the watermarked version of the published
article along with a disclaimer outlining the terms and conditions
of use.
ETHICAL POLICY
Current Gene Therapy adheres and follows the World Association
of Medical Jounals recommendations on publication ethics policies
for medical journals (http://www.wame.org/pubethicrecom.htm).
COMPETING FINANCIAL INTERESTS
In order to make our readers aware that interpretation of
published results may be biased due to vested interests, Current
Gene Therapy asks that authors describe all sources of financial
support for their research in the acknowledgement section
and add the following statement if they have potential competing
financial interests: "authors declare having potential
competing financial interests", without need of specifying
what type of competing financial interests exist. Competing
financial interests include funding from and employment by
organizations that may gain or lose financially through publication
of the article, as well as personal financial interests, such
as stocks and shares in companies that may gain or lose financially
through publication of the article, consultation fees or other
forms of remuneration from such companies/organizations, as
well as patents or patent applications whose value may be
affected by publication of the article. Otherwise, the following
statement should appear in the acknowledgement section: "authors
declare having no potential competing financial interests".
Copyright: It is a condition
of publication that manuscripts submitted to this journal
have not been published and will not be simultaneously submitted
or published elsewhere. Plagiarism is strictly forbidden,
and by submitting the article for publication the authors
agree that the publishers have the legal right to take appropriate
action against the authors, if plagiarism is discovered. By
submitting a manuscript the authors agree that the copyright
of their article is transferred to the publishers if and when
the article is accepted for publication.
PERMISSIONS
Part of the Journal contents may be reproduced for personal
use. The Publisher's consent does not extend, however to copying
for general distribution, for promotion, for creating new
works, or for resale. Specific permission must be obtained
from the Publisher for such copying. Requests must be sent
to the Permission Department at permission@bentham.org.
SUBSCRIPTIONS
Current rates are listed on our website at http://www.bentham.org
in the "SUBSCRIBE" section where you can subscribe
online. For individual and multiple journal subscriptions,
possible discounts and global online licenses, please contact
our sales department at sales@bentham.org
FREE SAMPLE COPIES
A free sample issue can be viewed on the journal's website.
Alternatively a free print sample may be requested, please
send your request to sample.copy@bentham.org
CURRENT GENE THERAPY ONLINE
This publication is available online from Ingenta at www.ingenta.com
Individual articles are also available online for sale via
Infotrieve at www.infotrieve.com
or from Ingenta at www.ingenta.com
.
ADVERTISING
To place an advertisement in this journal please contact the
advertising department at ads@bentham.org
CURRENT GENE THERAPY EDITORIAL OFFICE
Editor-in-Chief
Dr. Ignacio Anegon, M.D. (peer-reviewed, indexed in
PubMed)
INSERM Unit 643
30, boulevard Jean Monnet
44093 Nantes
France
Tel: +33(0)240087410
Fax: +33(0)240087411
Email: cgt@univ-nantes.fr
Editorial Assistants
Aurélie Le Gal
Brenda Evans
INSERM Unit 643
30, boulevard Jean Monnet
44093 Nantes
France
Tel: +33(0)240087410
Fax: +33(0)240087411
Email: cgt@univ-nantes.fr |
